SL Science Holding Ltd 6-K, filed Oct 26, 2026

About this 6-K

SL Science Holding Ltd (SLBT)

6-K 2026-10-26 For: 2026-06-30

Added on October 26, 2026

For the Six Months Ended June 30

(Unaudited)

(Unaudited)

Operating cash outflows from operating lease

SL Science Holding Ltd filed this 6-K on October 26, 2026.

SL Science completed the Business Combination on June 12, 2026 and raised $7,800,000 through 780,000 PIPE units. For the six months ended June 30, 2026, revenue was $1,386,608, net loss was $(2,162,205), and cash and cash equivalents were $8,306,692. AI summary

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →



Exhibit No.		Description
99.1		Unaudited Interim Consolidated Financial Statements for the Six Months Ended June 30, 2026 and 2025
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations
99.3		Press Release
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).



	SL Science Holding Limited

Date: October 26, 2026	By:	/s/ William Wang
	Name:	William Wang
	Title:	Chief Executive Officer


Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025	F-2
Unaudited Interim Consolidated Statements of Operations and Comprehensive (Loss) Income for the six months ended June 30, 2026 and 2025	F-3
Unaudited Interim Consolidated Statements of Changes in Shareholders’ Equity for the six months ended June 30, 2026 and 2025	F-4
Unaudited Interim Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025	F-5
Notes to Unaudited Interim Consolidated Financial Statements	F-6



		June 30,			December 31,
	Note	2026			2025
		(Unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents		$	8,306,692		$	1,258,616
Inventories	3		73,267			—
Prepaid expenses and other current assets	4		234,340			167,612
Tax recoverable			—			597
TOTAL CURRENT ASSETS			8,614,299			1,426,825

Operating lease right-of-use assets, net	6		136,913			212,324
Plant and equipment, net	5		159,926			248,894
Deferred offering costs	7		—			929,137
TOTAL ASSETS		$	8,911,138		$	2,817,180

LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES
Operating lease liabilities, current	6	$	137,598			148,663
Accrued expenses and other liabilities	8		202,850			319,872
Due to Director	11		1,600,000			—
TOTAL CURRENT LIABILITIES			1,940,448			468,535

Operating lease liabilities, non-current	6		—			64,742
TOTAL LIABILITIES			1,940,448			533,277
Commitments and contingencies	10

Ordinary shares, $0.00001 par value; 4,950,000,000 shares authorized, 560,759,740 and 556,800,001 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively*	9	$	5,608		$	5,568
Series A preferred shares, $0.00001 par value, 50,000,000 shares authorized, 780,000 shares issued and outstanding as of June 30, 2026	9		8			—
Additional paid-in-capital	9		14,157,893			7,293,276
Accumulated deficits			(7,646,583)			(5,484,378)
Accumulated other comprehensive income			453,764			469,437
Total shareholders’ equity			6,970,690			2,283,903
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		$	8,911,138		$	2,817,180



		For the Six Months
		Ended June 30,
	Note	2026		2025
Revenue	2	$	1,386,608	$	1,129,238
Cost of revenue			(829,124)		(740,172)
Gross profit			557,484		389,066

Operating expenses
General and administrative expenses			1,489,663		1,281,786
Research and development expenses	2		1,229,998		268,451
Research and development expenses – related party	2,11		—		448,571
Total operating expenses			2,719,661		1,998,808

Loss from operations			(2,162,177)		(1,609,742)

Other income (expenses)
Other (expenses) income, net			(7,549)		(21,358)
Interest income			7,521		29,007
Total other income (expenses), net			(28)		7,649

Loss before income tax			(2,162,205)		(1,602,093)
Income tax credit (expense)			—		4
Net loss		$	(2,162,205)	$	(1,602,089)

Other comprehensive loss, net of tax:
Change in cumulative foreign currency translation			(15,673)		469,815
Comprehensive loss		$	(2,177,878)	$	(1,132,274)

Basic net (loss) income per share*			(0.00)		(0.00)
Basic weighted average number of shares outstanding*	2		557,215,664		556,800,001

Diluted net (loss) income per share*			(0.00)		(0.00)
Diluted weighted average number of shares outstanding*	2		557,215,664		556,800,001



														Accumulative
		Preferred				Ordinary				Additional				other		Total
		Shares				shares				paid-in		Accumulated		comprehensive		Shareholders’
		Shares		Amount		Shares*		Amount		capital		deficits		income		equity
				US$				US$		US$		US$		US$		US$
Six months ended June 30, 2026:
Balance at January 1, 2026		—		—		556,800,001		5,568		7,293,276		(5,484,378)		469,437		2,283,903
Conversion of Ordinary shares in connection with reverse recapitalization		—		—		3,179,739		32		398,043		—		—		398,075
Issuance of PIPE units		780,000		8		780,000		8		7,799,984		—		—		7,800,000
Transaction cost in connection with reverse recapitalization and issuance of PIPE units		—		—		—		—		(1,333,410)		—		—		(1,333,410)
Net loss for the period		—		—		—		—		—		(2,162,205)		—		(2,162,205)
Foreign currency translation adjustment		—		—		—		—		—		—		(15,673)		(15,673)
Balance at June 30, 2026		780,000		8		560,759,740		5,608		14,157,893		(7,646,583)		453,764		6,970,690

Six months ended June 30, 2025:
Balance at January 1, 2025		—		—		556,800,001		5,568		7,157,579		(1,664,560)		228,466		5,727,053
Reversal of prior year carve-out tax difference		—		—		—		—		135,697		—		—		135,697
Foreign currency translation adjustments		—		—		—		—		—		—		469,815		469,815
Net loss for the period		—		—		—		—		—		(1,602,089)		—		(1,602,089)
Balance at June 30, 2025		—		—		556,800,001		5,568		7,293,276		(3,266,649)		698,281		4,730,476



								% of
		Date of		Place of				Equity		Principal
Name of Entity		Incorporation		Incorporation		Shareholders		Ownership		Activities
SL Bio Limited		March 18, 2024		Cayman		SL Science		100%		Holding
SL Bio Co., Ltd (“SL Bio Taiwan”)		July 21, 2022		the Republic of China (“ROC” or “Taiwan”)		SL Bio		100%		research, development and sales of exosome products
Horizon Space Acquisition II Corp		March 21, 2023		Cayman		SL Science		100%		Inactive



Leasehold improvement		Over the shorter of lease term of the estimated useful lives of the assets
Machinery and equipment		5 years
Office equipment		5 years



		Corporate			Retail
		Customers			Customers	Total
Exosome concentrate		$	1,386,608		—	1,386,608
Total		$	1,386,608		—	1,386,608



		For the Six Months
		Ended June 30,
Supplier		2026		2025
Vendor A		100	%	100	%



		For the Six Months
		Ended June 30,
Customer		2026		2025
Customer A		82	%	—	%
Customer B		18	%	91	%



		Operating
		Lease
As of June 30, 2026		(Unaudited)
From July 1, 2026 to June 30, 2027
Present Value of future minimum lease payments		$	137,598
Less: Current obligations			(137,598)
Long term obligations		$	—



Name		Amount			Relationship		Note
Mr. Wang		$	1,600,000		a director and a shareholder of the Company		Loan to the Group, interest free and due for repayment on August 31, 2026



					CD-19			GDT cell			Corporate
		Exosome			Armed-T			therapy			and
		Products			Products			Products			Unallocated			Total
Revenue		$	1,386,608		$	—		$	—		$	—		$	1,386,608
Cost of revenue			(829,124)			—			—			—			(829,124)
Gross profit			557,484			—			—			—			557,484
Operating expenses			367,989			128,536			1,251,462			971,674			2,719,661
Operating profit (loss)			189,495			(128,536)			(1,251,462)			(971,674)			(2,162,177)
Other income (expenses), net			(28)			—			—			—			(28)
Profit (loss) before income tax			189,467			(128,536)			(1,251,462)			(971,674)			(2,162,205)

As of June 30, 2026
Identifiable long-lived assets			10,746			—			—			149,180			159,926
Total assets			695,816			—			—			8,215,322			8,911,138



				For the Six Months
				Ended June 30,
		Note		2026			2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss				$	(2,162,205)		$	(1,602,089)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expenses		5			84,838			5,937
Lease expenses		6			—			76,627

Changes in operating assets and liabilities
Inventories					(73,267)			650,498
Prepaid expenses and other current assets					175,773			195,674
Accrued expenses and other liabilities					(117,022)			167,346
Deferred tax liabilities					—			(4,390)
Amount due to an affiliate					—			444,477
Operating lease liabilities					(396)			(68,237)
Tax refund					597			—
Net cash (used in) operating activities					(2,091,682)			(134,157)

CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of plant and equipment		5			—			(317,676)
Net cash (used in) investing activities					—			(317,676)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from Director					1,600,000			—
Proceeds from reverse recapitalization					155,574			—
Proceeds from PIPE units					7,800,000			—
Payment of offering cost related to reverse recapitalization					(404,273)			(614,373)
Net cash provided by (used in) financing activities					9,151,301			(614,373)

Effect of change in exchange rate					(11,543)			473,972

NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS					7,048,076			(592,234)
Cash and cash equivalents, beginning of year					1,258,616			4,137,526
Cash and cash equivalents, end of year				$	8,306,692		$	3,545,292

SUPPLEMENTAL CASH FLOW INFORMATION:
Income taxes paid				$	—		$	—



		Corporate			Retail
		Customers			Customers		Total
Exosome concentrate		$	1,023,295		$	69,780	$	1,093,075
Skin care products			1,160			9,046		10,206
Hair care products			3,349			22,608		25,957
Total		$	1,027,804		$	101,434	$	1,129,238



		For the Six Months
		Ended June 30,
		2026		2025
Years ended NTD: US$1 exchange rate		31.89		29.11
Annual average NTD: US$1 exchange rate		31.62		31.88



		Corporate			Retail
		Customers			Customers			Total
Exosome concentrate		$	1,023,295		$	69,780		$	1,093,075
Skin care products			1,160			9,046			10,206
Hair care products			3,349			22,608			25,957
Total		$	1,027,804		$	101,434		$	1,129,238



		Six months ended
		June 30,
		2026			2025
Net cash used in operating activities		$	(2,091)		$	(134)
Net cash used in investing activities			—			(318)
Net cash provided by (used in) financing activities			9,151			(614)



	Payments Due In
	Less than		1 – 2	2 – 3	3 – 4	4 – 5
	1 year		years	years	years	years	Thereafter	Total
Operating lease liabilities^(a)	$	137	—	—	—	—	—	137
Total commitments	$	137	—	—	—	—	—	137

In thousands USD, except		For the six		For the six
percentage data, differences		months ended		months ended		Variance
due to rounding		June 30, 2026		June 30, 2025		%

Net Revenue		1,387		1,129		23	%
Cost of Revenue		(829)		(740)		12	%
Gross Profit		558		389		43	%
General and Administrative Expenses		1,490		1,282		16	%
Research and Development Expenses		1,230		717		72	%
Total Operating Expenses		2,720		1,999		36	%
Loss from Operations		(2,162)		(1,610)		34	%
Net Loss		(2,162)		(1,602)		35	%

		June 30, 2026			December 31, 2025
		(Unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents		$	8,306,692		$	1,258,616
Inventories			73,267			—
Prepaid expenses and other current assets			234,340			167,612
Tax recoverable			—			597
TOTAL CURRENT ASSETS			8,614,299			1,426,825

Operating lease right-of-use assets, net			136,913			212,324
Plant and equipment, net			159,926			248,894
Deferred offering costs			—			929,137
TOTAL ASSETS		$	8,911,138		$	2,817,180

LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES
Operating lease liabilities, current		$	137,598			148,663
Accrued expenses and other liabilities			202,850			319,872
Due to Director			1,600,000			—
TOTAL CURRENT LIABILITIES			1,940,448			468,535

Operating lease liabilities, non-current			—			64,742
TOTAL LIABILITIES			1,940,448			533,277

Ordinary shares, $0.00001 par value; 4,950,000,000 shares authorized, 560,759,740 and 556,800,001 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively*		$	5,608		$	5,568
Series A preferred shares, $0.00001 par value, 50,000,000 shares authorized, 780,000 shares issued and outstanding as of June 30, 2026			8			—
Additional paid-in-capital			14,157,893			7,293,276
Accumulated deficits			(7,646,583)			(5,484,378)
Accumulated other comprehensive income			453,764			469,437
Total shareholders’ equity			6,970,690			2,283,903
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		$	8,911,138		$	2,817,180


		For the Six Months Ended June 30,
		2026			2025
Revenue		$	1,386,608		$	1,129,238
Cost of revenue			(829,124)			(740,172)
Gross profit			557,484			389,066

Operating expenses
General and administrative expenses			1,489,663			1,281,786
Research and development expenses			1,229,998			268,451
Research and development expenses – related party			—			448,571
Total operating expenses			2,719,661			1,998,808

Loss from operations			(2,162,177)			(1,609,742)

Other income (expenses)
Other (expenses) income, net			(7,549)			(21,358)
Interest income			7,521			29,007
Total other income (expenses), net			(28)			7,649

Loss before income tax			(2,162,205)			(1,602,093)
Income tax credit (expense)			—			4
Net loss		$	(2,162,205)		$	(1,602,089)

Other comprehensive loss, net of tax:
Change in cumulative foreign currency translation			(15,673)			469,815
Comprehensive loss		$	(2,177,878)		$	(1,132,274)

Basic net (loss) income per share*			(0.00)			(0.00)
Basic weighted average number of shares outstanding*			557,215,664			556,800,001

Diluted net (loss) income per share*			(0.00)			(0.00)
Diluted weighted average number of shares outstanding*			557,215,664			556,800,001